Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIP-S: Secukinumab for Aortic Vascular Inflammation in Psoriasis
NCT02690701Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2016
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in plaque psoriasis comparing Secukinumab with Placebo then Secukinumab (2 arms). Primary endpoint: Aortic Vascular Inflammation as Measured by FDG-PET/CT at 12 weeks. Started Feb 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02690701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02690701.